Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;3(1):71-81.
doi: 10.2217/hep.15.42. Epub 2015 Nov 30.

Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China

Shukui Qin  1 , Xinlei Gong  1
Affiliations
Review

Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China

Shukui Qin et al. Hepat Oncol. 2016 Jan.

Abstract

Hepatocellular carcinoma (HCC) characterized by insidious onset is a highly invasive malignance and has a rapid progress. The majority of patients, especially in Asian countries, present with locally advanced or distant metastatic disease at diagnosis and are not eligible for local treatment. Before the publication of the EACH study results showing the survival benefits of the FOLFOX 4 regimen in Chinese patients with advanced HCC, no chemotherapeutical drug or regimen was considered as systemic chemotherapy standard for this group of patients due to the lack of evidence-based recommendations. Oxaliplatin-containing regimens have shown clinical activity against advanced HCC with an acceptable safety profile. The aim of this article is to present a review of the scientific evidence mainly originating from China that supports the recommendation of oxaliplatin-based regimens for the treatment of Chinese patients with advanced HCC.

Keywords: hepatocellular carcinoma; oxaliplatin; oxaliplatin-based regimens; systemic chemotherapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J, Soerjomataram I, Ervik M, et al. Lyon, France: International Agency for Research on Cancer; 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11.http://globocan.iarc.fr

    2. • Statistical data showing hepatocellular carcinoma (HCC) is a worldwide common cancer with especially higher incidence and mortality in China.

    1. Fan J, Yang GS, et al. Liver transplantation outcomes in 1078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J. Cancer Res. Clin. Oncol. 2009;135:1403–1412. - PubMed
    1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. - PubMed

    2. • Phase III, randomized, double-blind and placebo-controlled trial showing sorafenib could prolong the survival of patients with advanced HCC in the Asia–Pacific region.

    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008;359:378–390. - PubMed

    2. • Phase III, randomized, multicenter, placebo-controlled trial showing sorafenib could prolong the survival of European/American patients with advanced HCC.

    1. Gong X, Qin S. Progression of Clinical and Laboratory Studies on Systemic Chemotherapy with Oxiliplatin-Combined Regimens in Advanced Hepatocellular Carcinoma. Chin. J. Front. Med. Sci. 2014;6:22–33.

LinkOut - more resources